10X1000-TECH
5.3.2024 14:28:31 CET | Business Wire | Press release
The Global Digital Talent Community 10x1000 Tech for Inclusion (“10x1000”) and FINOLAB, a Tokyo-based fintech office and business community, have entered into a collaborative effort to enhance digital capacity and drive digital economic growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305260615/en/
The Global Digital Talent Community 10x1000 Tech for Inclusion (“10x1000”) and FINOLAB have entered into a collaborative effort to enhance digital capacity and drive digital economic growth. (Photo: Business Wire)
Pursuant to a signed Memorandum of Understanding (MoU), FINOLAB will collaborate with 10x1000 to identify and invite qualified participants through its network of member institutions, partners, affiliates, and other stakeholders to participate in the learning programs provided by 10x1000. Participants will be afforded the opportunity to serve as both learners and industry experts.
Additionally, the two organizations will work together to develop learning content that highlights and promotes the digital landscape and opportunities in Japan and drive knowledge sharing through their respective networks.
The MoU was signed by Jennifer Tan, Program Head for 10x1000 Tech for Inclusion, and Makoto Shibata, Head of FINOLAB and Chief Community Officer at FINOLAB. The signing ceremony was witnessed by Sopnendu Mohanty, Chief Fintech Officer at the Monetary Authority of Singapore, Leiming Chen, Chief Sustainability Officer of Ant International and Senior Vice President at Ant Group, and Chie Ito, Chief Executive Officer of FINOLAB.
“We are honored to join hands with FINOLAB to extend the network of 10x1000 in terms of both learners and lecturers, which will benefit the community profoundly. This collaboration marks a pivotal moment in our journey towards cultivating a vibrant and inclusive talent development ecosystem, where innovation knows no boundaries,” said Ms. Tan.
“Our members would benefit immensely from the knowledge accumulation of 10x1000 and we may also be able to contribute our experiences in Japan to the 10x1000 community members. The collaboration would be an appropriate opportunity for all of us to appreciate the true value of open innovation,” commented Mr. Shibata.
By the year 2023, 10x1000 has certified a total of 6,243 learners from over 100 countries and regions. The Philippines, Indonesia, Thailand, Bangladesh, and Nigeria were the top five countries from which most learners came. Of the certified learners, females accounted for 49% of the total learner base. It is noteworthy that the certified learners represent more than 2,000 organizations, and nearly 80% of them are micro, small, or medium-sized enterprises (MSMEs).
About 10x1000 Tech for Inclusion
10x1000 Tech for Inclusion is an open and global learning community that enables learners to become drivers of digital economic growth. Its mission is to nurture and inspire at least 1,000 emerging talents and tech leaders each year for the next ten years. 10x1000 is a philanthropic initiative launched jointly by the International Finance Corporation (IFC), a member of the World Bank Group, and Alipay in 2018.
About FINOLAB
FINOLAB is a membership business community and an office space located in the heart of international financial district in Tokyo to promote FinTech ecosystem and open innovation. Launched in Feb. 2016 by Mitsubishi Estate and Dentsu Group as the first FinTech Center in Japan, it consists of stakeholders, including startups, corporates, and regulators.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305260615/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom